What is Caris Life Sciences?
Founded in 2008, Caris Life Sciences operates at the intersection of advanced data analytics and clinical oncology. The company is a leader in the precision medicine space, utilizing transformative technologies to analyze molecular data and provide comprehensive tumor profiling. By delivering high-quality diagnostic information, Caris enables clinicians to make more informed, personalized treatment decisions, thereby improving patient outcomes. Its market position is defined by its commitment to trailblazing the path toward more effective, data-informed healthcare solutions, effectively bridging the gap between complex biological data and clinical application.
How much funding has Caris Life Sciences raised?
Caris Life Sciences has raised a total of $3.6B across 7 funding rounds:
Unspecified
$150M
Unspecified
$310M
Other Financing Round
$830M
Debt
$400M
Other Financing Round
$168M
IPO
$494M
Debt
$1.2B
Unspecified (2018): $150M with participation from Sixth Street Partners
Unspecified (2020): $310M led by Millennium Management, Coatue Management, T. Rowe Price Associates, Neuberger Berman, OrbiMed, ClearBridge Investments, Highland Capital Management , L.P., and First Light Asset Management
Other Financing Round (2021): $830M supported by Pura Vida Investments, ClearBridge Investments, Tudor Investment Corporation, Columbia Threadneedle, Rock Springs Capital, Coatue, Millennium Management Global Investment, Sixth Street, Eaton Vance Management, Highland Capital Management, OrbiMed, Fidelity Management, First Light Asset Management, CPP Investments, Silver Lake, T. Rowe Price, and Neuberger Berman
Debt (2023): $400M featuring Braidwell and OrbiMed
Other Financing Round (2025): $168M backed by Braidwell, Ghisallo Capital Management, Woodline Partners, and Perceptive Advisors
IPO (2025): $494M, investors not publicly disclosed
Debt (2026): $1.2B led by Blue Owl and Blackstone
Key Investors in Caris Life Sciences
OrbiMed
A specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains including biopharmaceuticals and diagnostics.
Sixth Street Partners
A leading global investment firm dedicated to providing flexible, long-term capital and innovative solutions to companies across diverse sectors including healthcare.
Coatue Management
An employee-owned hedge fund sponsor that invests in public and private equity, with a strong focus on technology and healthcare-related growth businesses.
What's next for Caris Life Sciences?
Looking ahead, the strategic deployment of the $1.2B will likely focus on accelerating the development of next-generation diagnostic platforms and expanding the company's reach into new therapeutic domains. As Caris Life Sciences moves beyond its current lifecycle stage, the focus will shift toward operational optimization and the scaling of its data-enabled capabilities. The continued support from sophisticated investment partners suggests a long-term commitment to maintaining a competitive edge in the life sciences sector, with an emphasis on driving innovation that addresses critical unmet medical needs and enhances the efficacy of precision medicine on a global scale.
See full Caris Life Sciences company page
